Hypofractionated Palliative Radiotherapy in Patients With Advanced Non-operable Rectal Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

rectal cancer radiotherapy: Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.

Study summary

Many patients with rectal cancer were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this prospective study is to describe the preliminary results of our protocol of hypofractionated palliative radiotherapy in patients with non-operable rectal cancer.

Eligibility

Primary outcome measure(s)

• Symptomatic response after palliative radiotherapy (bleeding) — two months afer the end of radiotherapy
  number of patients with bleeding ( worst, no change, better or without)
• Symptomatic response after palliative radiotherapy (pain) — two months afer the end of radiotherapy
  number of patients with pain ( worst, no change, better or without)
• Gastrointestinal toxicity after the end of radiotherapy — two months afer the end of radiotherapy
  Gastrointestinal toxicity after the end of radiotherapy were reported according to CTCAE v4.0 scale
• Genitourinary toxicity after the end of radiotherapy — two months afer the end of radiotherapy
  Genitourinary toxicity after the end of radiotherapy were reported according to CTCAE v4.0 scale.

Trial sites (1)

More Consorci Sanitari de Terrassa trials in Spain

Other trials for the same condition